members only »

About us

The SSG was formed in 1979 by physicians and scientists from the Scandinavian countries with a primary interest in tumors of connective tissues.

The goal of the SSG is to advance the care of patients with sarcoma and to increase knowledge of all aspects of the biology of these tumors, including basic and clinical research. The SSG has developed treatment protocols for different sarcoma types and participates in international clinical trials.

At this SSG web-site you can access treatment protocols, find information about previous and future SSG meetings with links to SSG publications.

SSG secretary: Eva-Mari Olofsson
SSG mail address:

The Scandinavian Sarcoma Group is a part of Lund University and follows the instructions/regulations for data protection for Lund University.

For more information please, follow this link

The data from ISG/SSG IV (metastatic Ewing sarcoma) was published in Annals of Oncology (2012;23;2970-6). The median follow-up for survivors was 62 months (range 24–124). The 5-year EFS probability was 0.43 and the 5-year OS probability was 0.52. The most important prognostic factors for poor prognosis were (i) a poor histological or radiological response at the primary tumor site and (ii) an incomplete remission of lung metastases after primary chemotherapy.

The oncology group in SSG has agreed on that these results should influence on SSG`s treatment strategy in the future. The protocol ISG/SSG IV, including HD-BuMel and total lung irradiation, is defined as standard treatment for metastatic Ewings sarcoma for selected patients, provided the following are observed after primary chemotherapy: 1. a good response at the site of primary tumor  2. complete remission of lung metastases.